Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
125.37
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Apr 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
81
82
Next >
FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI
December 14, 2023
From
Merck & Co., Inc.
Via
Business Wire
MRNA Stock Surges as Moderna Teams Up With Merck to Fight Cancer
December 14, 2023
Moderna is in focus after reporting positive results for its cancer treatment today, with MRNA stock surging more than 9%.
Via
InvestorPlace
Moderna CEO Highlights Promising Cancer Vaccine Data: 'Think About The Number Of Lives That Can Be Impacted'
December 14, 2023
Moderna, Inc. (NASDAQ: MRNA) CEO Stéphane Bancel appeared on CNBC's "Squawk Box" Thursday to discuss the company's promising new cancer vaccine developed in
Via
Benzinga
Why Is Moderna (MRNA) Stock Up 11% Today?
December 14, 2023
Moderna stock is on the rise Thursday as investors in MRNA react to positive results from a skin cancer vaccine in a Phase 2b trial.
Via
InvestorPlace
(MRK) - Analyzing Merck & Co's Short Interest
December 04, 2023
Via
Benzinga
Price Over Earnings Overview: Merck & Co
November 30, 2023
Via
Benzinga
Analyst Ratings for Merck & Co
November 29, 2023
Via
Benzinga
Moderna Stock Is Soaring Today - Here's Why
December 14, 2023
Moderna Inc (NASDAQ: MRNA) and Merck & Co Inc (NYSE: MRK) announced follow-up data from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study of mRNA-4157 (V940), an investigational individualized...
Via
Benzinga
Moderna's Cancer Vaccine Cuts Risk Of Relapse, Death By 49%; Will Shares Jump?
December 14, 2023
Moderna and Merck are already working on a Phase 3 study, but these are long-running tests.
Via
Investor's Business Daily
Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following
December 14, 2023
Via
ACCESSWIRE
Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years?
December 14, 2023
Pfizer recently outlined expectations for 2024 results in light of an upcoming $43 billion acquisition of Seagen.
Via
The Motley Fool
Dow Jones Skyrockets To Record Heights, Shatters 37,000 Mark, Fueled By Fed's Dovish Stance
December 13, 2023
The 30 largest blue-chip stocks in the Dow Jones Industrial Average surged to unprecedented highs following the Federal Reserve's decision to keep interest rates steady.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
What's Going On With Moderna Stock Today?
December 12, 2023
Moderna Inc (NASDAQ: MRNA) announced changes to its operating model to bring focus to its short- and
Via
Benzinga
Why Is C4 Therapeutics (CCCC) Stock Up 72% Today?
December 12, 2023
C4 Therapeutics stock is rising higher on Tuesday as investors in CCCC shares celebrate a new collaboration agreement with Merck.
Via
InvestorPlace
Why Is Cancer-Focused C4 Therapeutics Stock Soaring Today?
December 12, 2023
C4 Therapeutics Inc (NASDAQ: CCCC) has entered into an exclusive license and collaboration agreement with Merck & Co Inc (NYSE: MRK) to develop degrader-antibody conjugates (DACs), an emerging modality...
Via
Benzinga
Biotech Is Coming Back, Can The Run Last?
December 11, 2023
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally.
Via
Talk Markets
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
December 11, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Animal Health Receives Positive CVMP Opinion for an Injectable Formulation of BRAVECTO® (Fluralaner) for Use in Dogs
December 11, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer
December 08, 2023
Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) announced that the Phase 3 LEAP-001 trial of Keytruda (pembrolizu
Via
Benzinga
Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
December 08, 2023
From
Merck & Co., Inc.
Via
Business Wire
Double Flops For Merck's Lung Cancer Studies
December 07, 2023
Merck & Co Inc (NYSE: MRK) announced full results from the Phase 2 KeyVibe-002 trial of vibostolimab/pembrolizumab combo, with or without docetaxel for metastatic non-small cell lung cancer (NSCLC)...
Via
Benzinga
Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility
December 07, 2023
From
Merck & Co., Inc.
Via
Business Wire
5 Dividend Stocks That Recently Increased Their Payouts
December 06, 2023
One stock increased its dividend by 25%.
Via
The Motley Fool
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments
December 02, 2023
LianBio received a $465 million buyout offer from Tang Capital Management. In addition, Tang also offered shareholders a contingent value right for 80% of net proceeds from any license or divestment of...
Via
Talk Markets
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer
November 30, 2023
From
Merck & Co., Inc.
Via
Business Wire
AWS and Accenture Help Merck Use Cloud Technology to Reduce Drug Discovery Time and Accelerate Clinical Trial Development
November 29, 2023
From
Amazon.com, Inc.
Via
Business Wire
PFAS's Forever Problem: Ohio Lawsuit Against Chemical Companies Fizzles Out
November 28, 2023
Big chemical companies won a lawsuit preventing 11.8 million Ohio residents from suing them for PFAS chemicals in their blood.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Merck Announces First-Quarter 2024 Dividend
November 28, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's
November 28, 2023
Merck & Co Inc (NYSE: MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent
Via
Benzinga
Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older
November 28, 2023
From
Merck & Co., Inc.
Via
Business Wire
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
81
82
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.